Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project

Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy

(2021) Stefania Spila Alegiani et al.   RHEUMATOLOGY

Calibrating real‐world evidence studies against randomized trials: treatment effectiveness of infliximab in Crohn’s disease

(2021) Julien Kirchgesner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Different Strategies to Execute Multi‐Database Studies for Medicines Surveillance in Real‐World Setting: A Reflection on the European Model

(2020) Rona Gini et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Biologics increase the risk of SARS ‐ CoV ‐2 infection and hospitalization, but not ICU admission and death: Real‐life data from a large cohort during red‐zone declaration

(2020) Giovanni Damiani et al.   Dermatologic Therapy

Impact of Anti-TNF and Thiopurines medications on the development of COVID-19 in patients with inflammatory bowel disease: A Nationwide VA cohort study

(2020) Nabeel Khan et al.   GASTROENTEROLOGY

Should patients stop their biologic treatment during the COVID-19 pandemic

(2020) Arjun M. Bashyam et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Should biologics for psoriasis be interrupted in the era of COVID-19?

(2020) Mark Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks

(2020) Salvatore Crisafulli et al.   BIODRUGS

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients

(2020) Gianluca Trifirò et al.   DRUG SAFETY

Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases

(2020) Kristin E Burke et al.   INFLAMMATORY BOWEL DISEASES

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 3

(2020) Ted R. Mikuls et al.   Arthritis & Rheumatology

Survival of Hospitalized COVID-19 Patients in Northern Italy: A Population-Based Cohort Study by the ITA-COVID-19 Network

(2020) Eliana Ferroni et al.   Clinical Epidemiology

Utilization patterns and characteristics of users of biologic anti‐inflammatory agents in a large, US commercially insured population

(2020) Aaron B. Mendelsohn et al.   Pharmacology Research & Perspectives

Challenges in Post-marketing Studies of Biological Drugs in the Era of Biosimilars: A Report of the International Society for Pharmacoepidemiology 2019 Mid-Year Meeting in Rome, Italy

(2019) Ylenia Ingrasciotta et al.   BIODRUGS

Review of European registries for psoriasis

(2018) Mina Amin et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence

(2017) Gianluca Trifirò et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

How did the Introduction of Biosimilar Filgrastim Influence the Prescribing Pattern of Granulocyte Colony-Stimulating Factors? Results from a Multicentre, Population-Based Study, from Five Italian Centres in the Years 2009–2014

(2016) Ilaria Marcianò et al.   BIODRUGS

How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009–2013

(2015) Ylenia Ingrasciotta et al.   BIODRUGS

Risk Management Plans as a Tool for Proactive Pharmacovigilance: A Cohort Study of Newly Approved Drugs in Europe

(2014) N S Vermeer et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database

(2014) Paola M. Cutroneo et al.   DRUG SAFETY

Initiation of Anti-TNF Therapy and the Risk of Optic Neuritis: From the Safety Assessment of Biologic ThERapy (SABER) Study

(2012) Kevin L. Winthrop et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Biologic registries in rheumatology: Lessons learned and expectations for the future

(2012) Ori Elkayam et al.   AUTOIMMUNITY REVIEWS

Electronic healthcare databases for active drug safety surveillance: is there enough leverage?

(2012) Preciosa M. Coloma et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry

(2010) Roberto Caporali et al.   AUTOIMMUNITY REVIEWS

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

(2009) W. G. Dixon et al.   ANNALS OF THE RHEUMATIC DISEASES

Pharmacovigilance of Biopharmaceuticals

(2009) Thijs J. Giezen et al.   DRUG SAFETY